| Risk | High |
|---|---|
| Min SIP Amount | ₹500 |
| Expense Ratio | 2.64% |
| NAV | ₹11.28 (10 Jul 2020) |
|---|---|
| Fund Started | 28 Dec 2015 |
| Fund Size | ₹235 Cr |
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| Dr. Reddy's Laboratories Ltd. | Healthcare | Equity | 16.4% |
| Sun Pharmaceutical Inds. Ltd. | Healthcare | Equity | 15.5% |
| Divi's Laboratories Ltd. | Healthcare | Equity | 10.4% |
| Lupin Ltd. | Healthcare | Equity | 9.2% |
| Ipca Laboratories Ltd. | Healthcare | Equity | 6.0% |
| Aurobindo Pharma Ltd. | Healthcare | Equity | 5.5% |
| Cipla Ltd. | Healthcare | Equity | 5.2% |
| Abbott India Ltd. | Healthcare | Equity | 4.6% |
| Procter & Gamble Health Ltd. | Healthcare | Equity | 4.5% |
| Narayana Hrudayalaya Ltd. | Healthcare | Equity | 4.4% |
Tata India Pharma & HealthCare Fund Regular Growth is a Equity Mutual Fund Scheme launched by Tata Mutual Fund. This scheme was made available to investors on 28 Dec 2015. Rupesh Patel, Sonam Udasi is the Current Fund Manager of Tata India Pharma & HealthCare Fund Regular Growth fund.The fund currently has an Asset Under Management(AUM) of ₹235 Cr and the Latest NAV as of 10 Jul 2020 is ₹11.28.
The Tata India Pharma & HealthCare Fund Regular Growth is rated High risk. Minimum SIP Investment is set to 500. Minimum Lumpsum Investment is 5000. Exit load of 0.25% if redeemed within 3 months
The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns.
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.